Valisure LLC is careful to adjust its methodologies for testing pharmaceuticals when the US Food and Drug Administration has questions, an approach the analytical laboratory would like the agency to consider about potential changes in its drug development and production rules.
Valisure Will Continue As 'Inconvenient' Reminder For Change To US Drug Quality ‘Status Quo’
“I think the symptoms of the core disease of quality is not having an independent layer or just not being able to invest more in quality or whatever the other root causes of addressing these quality issues,” says analytical lab president David Light.
